The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

The Switzerland-based pharmaceutical company has been trying to crack the weight-loss boom currently dominated by Eli Lilly ...

When doses werer increased rapidly in a Phase I study, patients on Roche’s investigational oral GLP-1 receptor agonist experienced nausea, vomiting, constipation, diarrhea, as well as abdominal and ...

FRANKFURT (Reuters) -Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that ...

Shares in the Swiss pharma giant fell 4.5% in early European trading. The stock has gained 5% year to date, having jumped 7% in July after Roche said the once-daily drug, acquired through its $3 ...

Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans.

Roche RHHBY presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting. CT-996 is an investigational, once ...

For the second trading session in less than a week, Roche Holding ( RHHBY -6.02%) stock really took it on the chin Wednesday.

Roche (RHHBY) stock slid 5% Wednesday after Reuters reported that positive data released in July for Roche's obesity pill ...

Roche's experimental weight-loss pill, CT-996, showed promising early-stage trial results, causing shares to rise. However, ...